Quick Takeaways
- Martin Babler has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $385,278.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Martin Babler
- Location
- South San Francisco, CA
- Summary
- The estimated net worth of Martin Babler is at least $385,278 dollars as of 28 Jan 2026. Martin Babler is the President, CEO and Chairman, Director of ALUMIS INC. and owns shares of ALUMIS INC. (ALMS) stock worth about $385.3K.
- Signature
- /s/ Sanam Pangali, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Martin Babler and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: ALUMIS INC. ($385,278).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Martin Babler
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| ALMS | ALUMIS INC. | President, CEO and Chairman, Director | $385,278 | 26 Jan 2026 | ||
| ETNB | 89bio, Inc. | Director | 30 Oct 2025 | |||
| NGNE | Neoleukin Therapeutics, Inc. | Director | 08 Jun 2023 | |||
| PRLD | Prelude Therapeutics Inc | Director | 12 Jun 2025 |
Insider Transactions Reported by Martin Babler:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.